Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid),
Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus …

Two years have passed since WHO declared a pandemic state for SARS-CoV-2 infection.
COVID-19 pathogenesis consists of a first viral phase responsible for early symptoms …

This literature review focuses on the role of IL-6 in TBI or PTSD-induced neuroinflammation.
While TBI and PTSD are widely prevalent, these diagnoses are particularly common …

With the ongoing COVID-19 pandemic, the emergence of the novel Omicron variant in
November 2021 has created chaos around the world. Despite mass vaccination, Omicron …

Introduction: Remdesivir (REM) and monoclonal antibodies (mAbs) could alleviate severe
COVID-19 in at-risk outpatients. However, data on their use in hospitalized patients …

Introduction As the third year of the SARS-CoV-2 pandemic approaches, COVID-19
continues to cause substantial morbidity and mortality due to waning vaccine efficacy and …

Harnessing the innate power of T cells for therapeutic benefit has seen many shortcomings
due to cytotoxicity in the past, but still remains a very attractive mechanism of action for …

Introduction Antidepressants are widely used for the pharmacological treatment of anxiety
and mood disorders. Since the eruption of the SARS-COV-2 pandemic and the later …

The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
outbreak, which causes COVID-19, had a devastating impact on both people's lives and the …

Interleukin 6 (IL-6) receptor inhibitors tocilizumab and sarilumab have recently been
approved for severe coronavirus disease 2019 (COVID-19). They also affect mood, even …